Logo image of EKSO

EKSO BIONICS HOLDINGS INC (EKSO) Stock Price, Forecast & Analysis

USA - NASDAQ:EKSO - US2826444000 - Common Stock

4.85 USD
-0.4 (-7.62%)
Last: 11/6/2025, 8:00:02 PM
5.2 USD
+0.35 (+7.22%)
Pre-Market: 11/7/2025, 4:42:33 AM

EKSO Key Statistics, Chart & Performance

Key Statistics
Market Cap12.66M
Revenue(TTM)14.75M
Net Income(TTM)-10.66M
Shares2.61M
Float2.46M
52 Week High14.97
52 Week Low2.73
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-5.68
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO2013-04-10
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment


EKSO short term performance overview.The bars show the price performance of EKSO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40 60

EKSO long term performance overview.The bars show the price performance of EKSO in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of EKSO is 4.85 USD. In the past month the price decreased by -9.18%. In the past year, price decreased by -62.4%.

EKSO BIONICS HOLDINGS INC / EKSO Daily stock chart

EKSO Latest News, Press Relases and Analysis

EKSO Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES25.04217.47B
ISRG INTUITIVE SURGICAL INC63.62196.37B
BSX BOSTON SCIENTIFIC CORP33.58146.77B
SYK STRYKER CORP26.86135.27B
IDXX IDEXX LABORATORIES INC56.657.10B
BDX BECTON DICKINSON AND CO12.350.85B
EW EDWARDS LIFESCIENCES CORP32.0848.40B
RMD RESMED INC25.2236.43B
GEHC GE HEALTHCARE TECHNOLOGY16.1633.86B
PODD INSULET CORP76.4522.76B
DXCM DEXCOM INC31.1922.75B
ZBH ZIMMER BIOMET HOLDINGS INC10.9417.53B

About EKSO

Company Profile

EKSO logo image Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company is headquartered in San Rafael California, California and currently employs 61 full-time employees. The company went IPO on 2013-04-10. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. The company operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.

Company Info

EKSO BIONICS HOLDINGS INC

101 Glacier Point, Suite A

San Rafael California CALIFORNIA 94804 US

CEO: Jack Peurach

Employees: 64

EKSO Company Website

EKSO Investor Relations

Phone: 15109841761

EKSO BIONICS HOLDINGS INC / EKSO FAQ

Can you describe the business of EKSO BIONICS HOLDINGS INC?

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company is headquartered in San Rafael California, California and currently employs 61 full-time employees. The company went IPO on 2013-04-10. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. The company operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.


What is the stock price of EKSO BIONICS HOLDINGS INC today?

The current stock price of EKSO is 4.85 USD. The price decreased by -7.62% in the last trading session.


Does EKSO stock pay dividends?

EKSO does not pay a dividend.


What is the ChartMill rating of EKSO BIONICS HOLDINGS INC stock?

EKSO has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Can you provide the sector and industry classification for EKSO BIONICS HOLDINGS INC?

EKSO BIONICS HOLDINGS INC (EKSO) operates in the Health Care sector and the Health Care Equipment & Supplies industry.


Should I buy EKSO stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on EKSO.


What is the outstanding short interest for EKSO BIONICS HOLDINGS INC?

The outstanding short interest for EKSO BIONICS HOLDINGS INC (EKSO) is 4.18% of its float.


EKSO Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to EKSO. When comparing the yearly performance of all stocks, EKSO turns out to be only a medium performer in the overall market: it outperformed 43.13% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

EKSO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to EKSO. EKSO has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

EKSO Financial Highlights

Over the last trailing twelve months EKSO reported a non-GAAP Earnings per Share(EPS) of -5.68. The EPS increased by 41.74% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -49.21%
ROE -110.14%
Debt/Equity 0.31
Chartmill High Growth Momentum
EPS Q2Q%64%
Sales Q2Q%2.37%
EPS 1Y (TTM)41.74%
Revenue 1Y (TTM)-16.59%

EKSO Forecast & Estimates

8 analysts have analysed EKSO and the average price target is 35.45 USD. This implies a price increase of 630.82% is expected in the next year compared to the current price of 4.85.

For the next year, analysts expect an EPS growth of 47.03% and a revenue growth -7.06% for EKSO


Analysts
Analysts82.5
Price Target35.45 (630.93%)
EPS Next Y47.03%
Revenue Next Year-7.06%

EKSO Ownership

Ownership
Inst Owners2.14%
Ins Owners5.93%
Short Float %4.18%
Short Ratio2.1